Assessing the cost-effectiveness of Epstein-Barr virus screening in young men initiating combination therapy with infliximab and azathioprine for Crohn's disease

被引：0
|
作者：
Fennimore, B. [1 ]
Gerich, M. E. [1 ]
Barnes, E. L. [2 ]
Hans, A. K. [3 ]
Herfarth, H. H. [2 ]
Scott, F. I. [1 ,4 ]
机构：
[1] Univ Colorado, Div Gastroenterol & Hepatol, Sch Med, Aurora, CO USA
[2] Univ North Carolina Chapel Hill, Div Gastroenterol & Hepatol, Chapel Hill, NC USA
[3] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA
[4] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P790
引用
收藏
页码：S511 / S511
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China
    Haotian Chen
    Jihao Shi
    Yipeng Pan
    Zhou Zhang
    Hao Fang
    Ying Chen
    Wendong Chen
    Qian Cao
    Advances in Therapy, 2020, 37 : 431 - 449
  • [32] Primary gastrointestinal Epstein-Barr virus (EBV)-positive high grade B-cell lymphoma in the setting of azathioprine therapy for Crohn's disease.
    Calaminici, MR
    Sheaff, MT
    Norton, AJ
    Abercrombie, J
    Feakins, RM
    JOURNAL OF PATHOLOGY, 1998, 184 : 20A - 20A
  • [33] One Case of Epstein-Barr Virus Encephalitis from Pediatric Crohn's Disease After 6-Mercaptopurine and Infliximab Treatment
    Yu, Jindan
    Lv, Yao
    Luo, Youyou
    Fang, Youhong
    Chen, Jie
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (05) : 1653 - 1655
  • [34] Reversible Hodgkin's lymphoma associated with Epstein-Barr virus occurring during azathioprine therapy for SLE
    Evans, S. J.
    Watson, D. K.
    O'Sullivan, M.
    RHEUMATOLOGY, 2008, 47 (07) : 1103 - 1104
  • [35] De-Escalation of Therapy Is Not Cost-Effective in Patients With Crohn's Disease in Clinical Remission on Combination Therapy With Infliximab and Azathioprine
    Syal, Gaurav
    Almario, Christopher
    Melmed, Gil Y.
    Spiegel, Brennan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S349 - S349
  • [36] Predictors of Infliximab Failure After Azathioprine Withdrawal in Crohn's Disease Treated With Combination Therapy
    Oussalah, Abderrahim
    Chevaux, Jean-Baptiste
    Fay, Renaud
    Sandborn, William J.
    Bigard, Marc-Andre
    Peyrin-Biroulet, Laurent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (05): : 1142 - 1149
  • [37] Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease
    Bollard, CM
    Aguilar, L
    Straathof, KC
    Gahn, B
    Huls, MH
    Rousseau, A
    Sixbey, J
    Gresik, MV
    Carrum, G
    Hudson, M
    Dilloo, D
    Gee, A
    Brenner, MK
    Rooney, CM
    Heslop, HE
    JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (12): : 1623 - 1633
  • [38] Ileocaecal Epstein-Barr virus-positive lymphoproliferative disorder complicating Crohn's disease
    Calaminici, MR
    Sheaff, MT
    Norton, AJ
    Feakins, RM
    HISTOPATHOLOGY, 1999, 35 (04) : 388 - 390
  • [39] Hemophagocytic lymphohistiocytosis in Crohn's Disease associated to citomegalovirus (CMV) or Epstein-Barr virus (EBV)
    Sanchez, Y.
    Trigo, C.
    Marquez, C.
    Leo, E.
    Marquez, J. L.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S128 - S128
  • [40] Cost-Effectiveness of Nasopharyngeal Carcinoma Screening With Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide
    Miller, Jacob A.
    Le, Quynh-Thu
    Pinsky, Benjamin A.
    Wang, Hannah
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (07): : 852 - 862
12345